Focus Partners Advisor Solutions LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 51.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,403 shares of the biopharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $3,399,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the stock. Waddell & Associates LLC lifted its stake in shares of Regeneron Pharmaceuticals by 63.7% in the fourth quarter. Waddell & Associates LLC now owns 1,185 shares of the biopharmaceutical company’s stock valued at $915,000 after buying an additional 461 shares during the period. Cerity Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 66.7% in the fourth quarter. Cerity Partners LLC now owns 34,227 shares of the biopharmaceutical company’s stock valued at $26,418,000 after buying an additional 13,693 shares during the period. Orion Investment Co lifted its stake in shares of Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Orion Investment Co now owns 30,812 shares of the biopharmaceutical company’s stock valued at $23,783,000 after buying an additional 175 shares during the period. Franklin Resources Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares during the period. Finally, Erste Asset Management GmbH lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Erste Asset Management GmbH now owns 52,049 shares of the biopharmaceutical company’s stock valued at $40,471,000 after buying an additional 3,313 shares during the period. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Stock Up 0.8%
NASDAQ REGN opened at $616.18 on Wednesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average is $701.59 and its two-hundred day moving average is $741.02. The company has a market capitalization of $65.14 billion, a price-to-earnings ratio of 15.01, a PEG ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 1-year low of $503.25 and a 1-year high of $821.11.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.
Analyst Ratings Changes
REGN has been the subject of several research reports. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Finally, Canaccord Genuity Group reduced their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.
View Our Latest Stock Report on Regeneron Pharmaceuticals
Insiders Place Their Bets
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
